Skip to main content

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Author
Abstract
:

Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).

Year of Publication
:
2018
Journal
:
Journal of hypertension
Date Published
:
2018
ISSN Number
:
0263-6352
URL
:
http://Insights.ovid.com/pubmed?pmid=29334491
DOI
:
10.1097/HJH.0000000000001647
Short Title
:
J Hypertens
Download citation